根据一项新研究,在100天内进行与高级肺癌或皮肤癌患者延长存活期有关的免疫治疗,接种 mRNA COVID疫苗。 mRNA COVID vaccines within 100 days of immunotherapy linked to longer survival in advanced lung or skin cancer patients, per a new study.

一项新的研究将开始免疫疗法后100天内的MRNA COVID-19疫苗接种与高级肺癌或皮肤癌患者更长的存活期联系起来。 A new study links mRNA COVID-19 vaccination within 100 days of starting immunotherapy to longer survival in advanced lung or skin cancer patients. 来自MD Anderson和佛罗里达大学的研究人员分析了1,000多份记录,并发现了更好的结果,表明疫苗可以通过激活T细胞和增强肿瘤识别来增强免疫反应。 Researchers from MD Anderson and the University of Florida analyzed over 1,000 records and found improved outcomes, suggesting the vaccine may boost immune responses by activating T-cells and enhancing tumor recognition. 虽然结果大有希望并得到动物数据的支持,但调查结果是以追溯性数据为依据的,无法证明因果关系。 While results are promising and supported by animal data, the findings are based on retrospective data and cannot prove causation. 专家们强调,需要进行大规模、预期的临床试验,以证实其效果,目前正在进行第三阶段试验,招收500名病人。 Experts stress the need for large, prospective clinical trials to confirm the effect, with a Phase 3 trial underway to enroll 500 patients. 如果得到验证,这种方法可以扩大mRNA技术在癌症治疗中的应用. If validated, this approach could expand the use of mRNA technology in cancer treatment.